Sanderling Ventures — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics as first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia.
BiotechHealthtechLongevityMiramar, US
Hing C Wong(Executive Officer, Director)Hing C. Wong(Founder & CEO)Hing W.(Founder)inLee Flowers(Executive Officer)Rebecca Byam(Executive Officer)Peter Rhode(Executive Officer)
Board seatFred Middleton· per SEC Form D · $16M raise · filed Oct 2020
BiotechLa Jolla, US
Michael Dunn(Executive Officer, Director)Ken Stauderman(Executive Officer)Daniel Geffken(Executive Officer)Sudarshan Hebbar(Executive Officer)Eric W. Roberts(Executive Officer)Kenneth A. Stauderman(Executive Officer)
Board seatFred MiddletonRobert G. McNeil· per SEC Form D · $17.2M raise · filed May 2020
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.